Analysts have high confidence in ACADIA Pharmaceuticals, predicting an average annual growth rate of 42%. The company's lack of debt reduces concerns around repayments and makes it a less risky investment.
Several companies were in the spotlight due to various developments: Oracle ($甲骨文(ORCL.US)$) experienced a surge in after-hours trading, buoyed by cloud deals and AI demand. Acadia Pharmaceuticals ($阿卡迪亚(ACAD.US)$) saw its stock decline by 15% following the announcement of disappointing results from a Phase 3 trial. Vail Resorts ($Vail Resorts(MTN.US)$) reported a decrease in stock value after releasing results that were impacted by lower visits and snowfall. $阿莎娜(ASAN.US)$Asana rep...
$阿卡迪亚(ACAD.US)$Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study's primary endpoint, the change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score (-11.8 vs. -11.1; p=0.4825; effe...
Trytosaveabit楼主Jaguar8:
You and me both! Even if it has a great pipeline with others soon to be reported! These are dangerous plays for just that reason! Some are just a huge overreaction! Some are not though.
10baggerbamm :
no matter what time frame of a chart you pull up daily weekly monthly yearly it's a complete disaster. 10 years of wealth destroyed since covid.
ACADIA Pharmaceuticals Inc.'s low P/S ratio is due to its poor revenue outlook. Investors' gloomy expectations for future revenue growth are driving the low P/S ratio. These conditions will persist as a hurdle for the share price unless improved.
阿卡迪亚股票讨论
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$因塞特(INCY.US)$
$百济神州(BGNE.US)$
$阿卡迪亚(ACAD.US)$
$Madrigal Pharmaceuticals(MDGL.US)$
$Rhythm Pharmaceuticals(RYTM.US)$
$Revolution Medicines(RVMD.US)$
$Kymera Therapeutics(KYMR.US)$
$AbCellera Biologics(ABCL.US)$
$Bicycle Therapeutics(BCYC.US)$
$Edgewise Therapeutics(EWTX.US)$
$Immunocore(IMCR.US)$
$Kodiak Sciences(KOD.US)$
$Roivant Sciences(ROIV.US)$
...
Oracle ( $甲骨文(ORCL.US)$ ) experienced a surge in after-hours trading, buoyed by cloud deals and AI demand.
Acadia Pharmaceuticals ( $阿卡迪亚(ACAD.US)$ ) saw its stock decline by 15% following the announcement of disappointing results from a Phase 3 trial.
Vail Resorts ( $Vail Resorts(MTN.US)$ ) reported a decrease in stock value after releasing results that were impacted by lower visits and snowfall.
$阿莎娜(ASAN.US)$ Asana rep...
$BioCardia(BCDA.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Crinetics(CRNX.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$罗氏(ADR)(RHHBY.US)$ Phase 3
$阿卡迪亚(ACAD.US)$ Phase 3
$Sellas Life Sciences(SLS.US)$ Phase 3
$Aquestive Therapeutics(AQST.US)$ Phase 3
$Jaguar Health(JAGX.US)$ Phase 3
$Novocure(NVCR.US)$ Phase 3
$强生(JNJ.US)$ Phase 3
$辉瑞(PFE.US)$ Phase 3
$Palatin Technologies(PTN.US)$ Phase 3
$Annovis Bio(ANVS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Ironwood医药(IRWD.US)$ Phase 3
$阿里拉姆制药(ALNY.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$ $Novocure(NVCR.US)$ Phase 3
$罗氏(ADR)(RHHBY.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$阿卡迪亚(ACAD.US)$ Phase 3
$Sellas Life Sciences(SLS.US)$...
$Regenxbio(RGNX.US)$ Phase 3
$Annovis Bio(ANVS.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Ironwood医药(IRWD.US)$ Phase 3
$阿里拉姆制药(ALNY.US)$ Phase 3
$福泰制药(VRTX.US)$ Phase 3
$KalVista Pharmaceuticals(KALV.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$Novocure(NVCR.US)$ Phase 3
$罗氏(ADR)(RHHBY.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$Applied Therapeutics(APLT.US)$ Phase 3
$阿卡迪亚(ACAD.US)$ Phase 3...
暂无评论